CA2003382A1 - Methode de traitement de maladies vasculaires - Google Patents

Methode de traitement de maladies vasculaires

Info

Publication number
CA2003382A1
CA2003382A1 CA002003382A CA2003382A CA2003382A1 CA 2003382 A1 CA2003382 A1 CA 2003382A1 CA 002003382 A CA002003382 A CA 002003382A CA 2003382 A CA2003382 A CA 2003382A CA 2003382 A1 CA2003382 A1 CA 2003382A1
Authority
CA
Canada
Prior art keywords
amino
alkyl
loweralkyl
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002003382A
Other languages
English (en)
Inventor
Hollis D. Kleinert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2003382A1 publication Critical patent/CA2003382A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002003382A 1988-11-21 1989-11-20 Methode de traitement de maladies vasculaires Abandoned CA2003382A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27515188A 1988-11-21 1988-11-21
US275,151 1988-11-21

Publications (1)

Publication Number Publication Date
CA2003382A1 true CA2003382A1 (fr) 1990-05-21

Family

ID=23051068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002003382A Abandoned CA2003382A1 (fr) 1988-11-21 1989-11-20 Methode de traitement de maladies vasculaires

Country Status (4)

Country Link
EP (1) EP0444156A4 (fr)
CA (1) CA2003382A1 (fr)
GR (1) GR1001145B (fr)
WO (1) WO1990005531A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5244910A (en) * 1990-08-15 1993-09-14 Abbott Laboratories Renin inhibitors
ZA921381B (en) * 1991-03-01 1992-11-25 Fujisawa Pharmaceutical Co New use of amino acid derivatives
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP4067368A1 (fr) 2016-06-01 2022-10-05 Athira Pharma, Inc. Composés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3418491A1 (de) * 1984-05-18 1985-11-21 Merck Patent Gmbh, 6100 Darmstadt Diaminosaeurederivate
DE3438545A1 (de) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt Peptide
DE3538749A1 (de) * 1985-10-31 1987-05-07 Merck Patent Gmbh Peptide
DE3626130A1 (de) * 1986-08-01 1988-02-11 Merck Patent Gmbh Aminosaeurederivate
DE3640535A1 (de) * 1986-11-27 1988-06-01 Merck Patent Gmbh Peptide
US7490044B2 (en) * 2004-06-08 2009-02-10 Bose Corporation Audio signal processing

Also Published As

Publication number Publication date
GR1001145B (el) 1993-05-24
EP0444156A1 (fr) 1991-09-04
GR890100773A (en) 1990-12-31
EP0444156A4 (en) 1992-12-09
WO1990005531A1 (fr) 1990-05-31

Similar Documents

Publication Publication Date Title
AU639212B2 (en) Non-peptide renin inhibitors
JPH04503802A (ja) 血管疾患の治療用組成物
US4977277A (en) Functionalized peptidyl aminodiols and -triols 4-amino-5-cyclohexyl-3-hydroxy-1,2-oxopentane and derivatives thereof
US5032577A (en) Peptidylaminodiols
US5164388A (en) Heterocyclic peptide renin inhibitors
CA2000929A1 (fr) Peptides heterocycliques inhibiteurs de la renine
US4826815A (en) Renin inhibiting compounds
AU613956B2 (en) Peptidylheterocycles
US5122514A (en) Psoriasis treatment
EP0230266A2 (fr) Peptidylaminodiols et -triols fonctionnalisés
US4994477A (en) Heterocyclic renin inhibitors
CA2003382A1 (fr) Methode de traitement de maladies vasculaires
CA2021740A1 (fr) Peptidyl aminodiol inhibiteur de la remine
US5268361A (en) Hydroxyazido derivatives and related compounds as renin inhibitors
US5276031A (en) Method for treating renal disease
US5268374A (en) Non-peptide renin inhibitors
AU632895B2 (en) Method for treating renal disease
WO1989010751A1 (fr) Peptidyl aminodiols et triols fonctionnalises
IE902944A1 (en) Peptidyl difluorodiol renin inhibitors
KR940000754B1 (ko) 리닌-저해성 올리고펩티드, 그의 제조방법 및 용도
AU609774C (en) Peptidylaminodiols
IE911326A1 (en) Psoriasis treatment

Legal Events

Date Code Title Description
FZDE Dead